治疗心脏氨基粉症的新疗法
Olives Nguyen1, Daniel Kamna, Ahmad Masri
1Division of Cardiology, The Amyloidosis Center, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, USA.
Current opinion in cardiology
|January 17, 2025
概括
新的疗法正在改变心脏粉症治疗的方法. 转基因氨基粉症 (ATTR-CM) 和轻链氨基粉症 (AL-CM) 在基因沉默剂,稳定剂和新型药物方面表现有前途.
科学领域:
- 心血管医学 心血管医学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏 Amyloidosis,包括跨甲状腺素 (ATTR-CM) 和免疫球蛋白轻链 (AL-CM) 类型,提出了重要的治疗挑战.
- 现有的治疗方法有局限性,需要探索新的治疗策略.
研究的目的:
- 审查ATTR-CM和AL-CM治疗选择的最新进展.
- 突出新兴治疗方法及其对患者治疗结果的潜在影响.
主要方法:
- 对目前正在进行的临床试验和最近批准的治疗心脏粉样化症的综合性审查.
- 分析了包括ATTRibute-CM,HELIOS-B和CARDIO-TTRansform在内的关键研究数据.
- 评估新型治疗类,如基因沉默剂,稳定剂,CAR-T细胞和纤维素消耗剂.
主要成果:
- 在ATTR-CM中,tafamidis是基石,acoramidis最近获得FDA批准,vutrisiran显示有效性;eplontersen正在等待.
- 创新的ATTR-CM疗法如NTLA-2001 (CRISPR-Cas9) 和纤维素消耗剂正在开发中.
- 对于AL-CM,Dara-CyBorD是标准的;新型药物包括CAR-T细胞,双特异性抗体和像比尔塔米马布和安塞拉米马布这样的纤维细胞消耗剂.
结论:
- 心脏粉症的治疗场景正在迅速发展,有各种各样的基于机制的治疗方法.
- 目前正在进行的临床试验准备重新定义护理标准并改善患者的预后.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
378
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
378
01:26Heart Failure Drugs: Inotropic Agents
511
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
511
01:22Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160